Geneos Wealth Management Inc. - PUMA BIOTECHNOLOGY INC ownership

Quarter-by-quarter ownership
Geneos Wealth Management Inc. ownership history of PUMA BIOTECHNOLOGY INC
ValueSharesWeighting
Q3 2023$2,630
-25.5%
1,0000.0%0.00%
Q2 2023$3,530
+14.2%
1,0000.0%0.00%
Q1 2023$3,090
-27.0%
1,0000.0%0.00%
Q4 2022$4,230
+111.5%
1,0000.0%0.00%
Q3 2022$2,0000.0%1,0000.0%0.00%
Q2 2022$2,0000.0%1,0000.0%0.00%
Q1 2022$2,000
-33.3%
1,0000.0%0.00%
Q4 2021$3,000
-50.0%
1,0000.0%0.00%
Q3 2021$6,000
-25.0%
1,0000.0%0.00%
Q2 2021$8,000
-11.1%
1,0000.0%0.00%
Q1 2021$9,0000.0%1,0000.0%0.00%
Q4 2020$9,0000.0%1,0000.0%0.00%
Q3 2020$9,000
-10.0%
1,0000.0%0.00%
-100.0%
Q2 2020$10,000
+25.0%
1,0000.0%0.00%0.0%
Q1 2020$8,0000.0%1,0000.0%0.00%
Q4 2019$8,000
-27.3%
1,0000.0%0.00%
-100.0%
Q3 2019$11,000
-8.3%
1,0000.0%0.00%0.0%
Q2 2019$12,000
-68.4%
1,0000.0%0.00%
-66.7%
Q1 2019$38,000
+8.6%
1,000
+181.7%
0.00%0.0%
Q4 2017$35,000
-23.9%
355
-8.0%
0.00%
-40.0%
Q3 2017$46,0003860.01%
Other shareholders
PUMA BIOTECHNOLOGY INC shareholders Q4 2023
NameSharesValueWeighting ↓
HARVARD MANAGEMENT CO INC 600,000$45,216,0003.56%
Avalon Global Asset Management LLC 32,900$2,479,0001.79%
CORNERSTONE CAPITAL MANAGEMENT LLC 495,145$37,314,0001.58%
BB BIOTECH AG 521,991$39,337,0001.25%
WEATHERBIE CAPITAL, LLC 137,041$10,327,0001.20%
ADAGE CAPITAL PARTNERS GP, L.L.C. 5,686,668$428,527,0001.19%
TOBAM 318,384$23,994,0000.94%
Orbimed Advisors 1,195,500$90,093,0000.91%
Capital International Sarl 109,405$8,245,0000.74%
CAPITAL INTERNATIONAL LTD /CA/ 145,697$10,980,0000.73%
View complete list of PUMA BIOTECHNOLOGY INC shareholders